Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) shares were down 3.2% during trading on Thursday . The stock traded as low as $20.33 and last traded at $20.46. Approximately 9,646 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 93,109 shares. The stock had previously closed at $21.13.
Analysts Set New Price Targets
ORKA has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a research report on Friday, December 20th. Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Friday, September 13th. They issued a "buy" rating and a $40.00 target price for the company. Lifesci Capital started coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued an "outperform" rating and a $41.00 price objective on the stock. Leerink Partners began coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They set an "outperform" rating and a $44.00 target price for the company. Finally, Leerink Partnrs raised Oruka Therapeutics to a "strong-buy" rating in a report on Tuesday, September 17th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $43.17.
Check Out Our Latest Stock Report on Oruka Therapeutics
Oruka Therapeutics Stock Down 5.4 %
The firm has a market cap of $699.28 million, a price-to-earnings ratio of -3.19 and a beta of 0.78. The business has a 50 day moving average price of $24.13.
Hedge Funds Weigh In On Oruka Therapeutics
A number of large investors have recently modified their holdings of ORKA. The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics during the third quarter valued at approximately $1,037,000. FMR LLC bought a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $114,763,000. Great Point Partners LLC purchased a new position in Oruka Therapeutics in the 3rd quarter worth $12,614,000. Braidwell LP bought a new stake in Oruka Therapeutics in the third quarter worth $12,640,000. Finally, Janus Henderson Group PLC purchased a new stake in Oruka Therapeutics during the third quarter valued at about $5,840,000. 56.44% of the stock is owned by hedge funds and other institutional investors.
Oruka Therapeutics Company Profile
(
Get Free Report)
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
See Also
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
